Robert L. Jesse

Learn More
Although psilocybin has been used for centuries for religious purposes, little is known scientifically about its acute and persisting effects. This double-blind study evaluated the acute and longer-term psychological effects of a high dose of psilocybin relative to a comparison compound administered under comfortable, supportive conditions. The participants(More)
Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to(More)
CONTEXT Prior mechanistic studies reported that omeprazole decreases the platelet inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. OBJECTIVE To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). DESIGN,(More)
This dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions. Participants were 18 adults (17 hallucinogen-naïve).(More)
I. OVERVIEW OF THE ACUTE CORONARY SYNDROME ............................................................e357 A. Definition of Terms............................................e357 B. Pathogenesis and Management of ACS.............e357 II. USE OF BIOCHEMICAL MARKERS IN THE INITIAL EVALUATION OF ACS .........................e358 A. Diagnosis of Myocardial(More)
The Sixth Conference on the "Standards of Laboratory Practice Series", sponsored by the National Academy of Clinical Biochemistry (NACB), was held on August 4-5, 1998, at the Annual Meeting of the American Association for Clinical Chemistry, in Chicago, IL. An expert committee was assembled to write recommendations on the use of cardiac markers in coronary(More)
*American College of Cardiology Foundation Representative; †Society for Cardiovascular Angiography and Interventions Representative; ‡American Association for Clinical Chemistry Representative; §American College of Physicians Representative; American College of Emergency Physicians Representative; ¶American College of Chest Physicians Representative; #ACCF(More)
I. Overview of Analytical Issues for Heart Failure Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e95 A. Background. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .e95 II. Analytical Biomarker Issues . . . . . . . . . . . . . . . . . . .e96 A. Issues Related to B-Type Natriuretic Peptide (BNP) and N-Terminal proB-Type(More)
I. OVERVIEW OF ANALYTICAL ISSUES FOR ACUTE CORONARY SYNDROME (ACS) BIOMARKERS ............................................................548 A. Analytical Issues: Background ..........................548 II. ANALYTICAL BIOMARKER ISSUES....................548 A. Cardiac Troponin Specifications .......................548 B. Cardiac Biomarker(More)